North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...

In this article, we are going to take a look at where Dexcom, Inc. (NASDAQ ... almost the same as the government spends on the entire Medicare program. That's a staggering figure.

Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities ...

Additionally, the accelerating shift of some Medicare Advantage patients from DME to pharmacy channels adds complexity to DexCom's channel strategy. The company will need to demonstrate that it ...

DexCom stock slumped 40% to $64.70 in trading ... which sells competing glucose monitors, among Medicare patients. The slump in new patient sign-ups led to an utter collapse for the stock, which ...